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Abstract 
Precision medicine can improve patient management by guiding therapeutic decision based 
on molecular characteristics. The concept has been extensively addressed through the 
application of –omics based approaches. Proteomics attract high interest, as proteins reflect 
a “real-time” dynamic molecular phenotype. Focusing on proteomics applications for 
personalized medicine, a literature search was conducted to cover: a) disease prevention, b) 
monitoring/ prediction of treatment response, c) stratification to guide intervention and d) 
identification of drug targets. The review indicates the potential of proteomics for 
personalized medicine by also highlighting multiple challenges to be addressed prior to 
actual implementation. In oncology, particularly bladder cancer, application of precision 
medicine appears especially promising. The high heterogeneity and recurrence rates 
together with the limited treatment options, suggests that earlier and more efficient 
intervention, continuous monitoring and the development of alternative therapies could be 
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accomplished by applying proteomics-guided personalized approaches. This notion is 
backed by studies presenting biomarkers that are of value in patient stratification and 
prognosis, and by recent studies demonstrating the identification of promising therapeutic 
targets. Herein, we aim to present an approach whereby combining the knowledge on 
biomarkers and therapeutic targets in bladder cancer could serve as basis towards 
proteomics- guided personalized patient management. 
A. Concept of personalized medicine 
Precision medicine, also called personalized medicine, aims at supporting personalized 
treatment, e.g. by sub-grouping of the patients to identify those most likely to benefit from a 
specific treatment and/or those who will suffer from side effects and incur cost without 
gaining benefit from the intervention, etc [1]. The goal of personalized medicine is to 
streamline clinical decision making by tailoring the medical management to the individual 
molecular characteristics during all phases of medical care, like prevention, diagnosis, 
prognosis, treatment and follow-up monitoring. When disease (or disease progression) is 
detected timely and precisely the treatment options are generally more effective. 
Developments of the –omics-based approaches (genomics, transcriptomics, proteomics, 
metabolomics) in combination with advanced computational tools has provided a solid 
infrastructure to describe the health status of individuals in a more comprehensive 
manner. -Omics and systems biology approaches, in comparison to classical biochemical 
assays, allow for simultaneous detection of multiple features, providing a comprehensive 
description of the molecular background. This builds a concrete foundation for predictive, 
personalized, preventive and participatory medicine (known also as “P4 medicine”) [2]. P4 
medicine focuses on the understanding of molecular mechanisms associated with disease in 
a more holistic manner, the consolidation, thus of the complex biological information at the 
level of DNA, RNA, proteins and metabolites, as well the integration of the single -omics data 
in molecular networks, is a prerequisite [2]. However, transforming this innovative idea into 
technically and clinically feasible tools, is highly challenging due to several factors, including: 
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a) technological challenges (e.g. data acquisition and integration, data sharing and size of -
omics data), b) high disease heterogeneity, c) societal challenges (education and raising 
awareness about the possibilities of P4 medicine to community, clinicians, health care 
system) and d) ethical aspects (accessibility of the individual molecular profiles, and its 
possible exploitation by third parties) [2]. 
Particularly, the presence of phenotypic diversity precludes the effective treatment of all 
patients using the same drug and delays translation of clinical trials’ results (i.e. the newly 
developed drugs) to new standard treatment options. In order to increase the success rate of 
clinical trials, the efficiency of implementation and ultimately the therapy decision making, 
the concept of precision medicine has been recently adopted to describe the molecular data 
consolidation to: a) identify biology-driven drug targets and b) develop disease relevant 
biomarkers to stratify/ sub-group the patients that are likely to respond to the proposed 
therapy. To practically support the implementation of the biomarkers as stratification tools in 
clinical trials, several study designs have been suggested including biomarker-orientated 
pipelines, such as: i) frequentist adaptive designs (e.g. biomarker-strategy design, 
enrichment-design, biomarker-stratified [3], ii) Bayesian designs (Bayesian adaptive 
randomised design [4]) or iii) hybrid Bayesian-frequentist approaches [5]. These biomarker-
guided clinical trials open a new perspective for adaptation of the therapeutic intervention 
based on the specific molecular profiles of individual patients, rather than the conventional 
therapy decision means, where therapy is mostly guided by the symptoms or the results of 
the pathological examination [6]. 
Generally, all available drugs target proteins. In comparison to the analysis at the level of 
DNA or RNA, the analysis of the proteins displays more accurately the real-time dynamic cell 
phenotype, thus proteomics approaches offer an opportunity to identify the best suited 
biomarkers and drug targets (Figure 1). Specifically, proteins are the key building blocks of 
life, retaining a structural, functional and regulatory role, being thus responsible for the 
orchestration of biological functions. In principle, proteins’ function is the result of the genetic 
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information that is integrated through alternative splicing, translational and post-translational 
modifications and further supplemented by environmental factors. Therefore, proteomic 
changes describe the functional status of organism. Significant changes at the protein level 
provide information on specific disease-altered pathways, allowing to understand the 
molecular mechanisms associated with disease. Additionally, through the interpretation of 
the proteomics data using in silico approaches, proteins that are involved in several 
pathways and have a causative relationship to the disease initiation and progression, can be 
revealed. Due to the recent technological advancements in the field of proteomics- including, 
but not limited to the introduction of the high-resolution mass spectrometry, a global more 
thorough assessment of the proteins expressed at a certain period of time under specific 
conditions has become possible. Application of proteomics to analyze clinical specimens 
such as body fluids or tissue samples (a field also known as clinical proteomics), has 
recently become a more common approach to address clinically relevant questions and 
improve on available means for patients’ management (e.g. diagnosis, monitoring, therapy) 
[7-9]. In this review, we aim at providing an overview of the contribution of proteomics 
approaches in personalized medicine, by emphasizing on the applicability of proteomics 
techniques to improve on bladder cancer (BC) management. 
B. From proteomics to personalized medicine 
To assess the contribution of proteomics in personalized medicine to date, a literature 
search was conducted using the Web of Science database, as follows: TOPIC: (“proteom*” 
AND “personal*”) AND TITLE: (“personal*”). Only manuscripts defined as “ARTICLE” OR 
“REVIEW” types published within the last 5 years (2012 - 2017) were considered. By 
applying the above criteria, a total number of 195 papers were retrieved and further 
screened independently by the co-authors. Focus was placed on the original research 
articles that are describing the application of proteomics alone or in combination with other 
approaches in the context of personalized medicine. To provide an overview of the 
technological advancements, methodological articles devoted to the development of 
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analytical workflows/ tools in the proteomics field have been also included. Twenty studies 
(Supplementary Table 1) were selected by at least two co-authors. These are further 
described in this review, sub-categorized based on the intended context of use, wherever 
applicable. 
i. Health screening and disease prevention 
Molecular profiling can support screening, as it can provide with a dynamic assessment of 
the health and disease state. Continuous monitoring during frequent intervals allows for the 
detection of a disease prior to its onset or at an early stage, where treatment options are 
most effective. By employing this concept, Chen et al. established an integrative Personal 
Omics Profile (iPOP) of one generally healthy Individual (male), who had been monitored- 
over a period of 14 months [10]. The profile represents a pioneering study in the field of 
personalized medicine, since the health status of the selected Individual was monitored 
using multi-dimensional molecular profiling of blood components (including genomic, 
transcriptomic, proteomic, metabolomics and auto-antibody) across twenty time points. 
Through this longitudinal study, a dynamic picture of molecular changes across health and 
disease status (for example, during the monitoring two episodes of viral infections occurred) 
was acquired. Importantly, risk assessment based on molecular data indicated a high risk of 
type-2 diabetes. Subsequent monitoring of the Individual confirmed the development of the 
disease, supporting the value of molecular profiling to assess disease risk in healthy 
population [10]. Moreover, in a follow-up study [11], it has been demonstrated that the level 
of pathways’ differential expression computed based on the previously described iPOP was 
associated with the disease status, supporting the use of pathway analysis to monitor 
disease initiation and progression and evaluate therapeutic response [11]. 
ii. Prediction of treatment response 
Several studies have been published to address the need to improve treatment efficiency 
through the development of tools to predict drug response, mostly in the context of cancer 
(e.g. melanoma [12], lung cancer [13]) and kidney diseases (IgA nephropathy [14]). Krepler 
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et al. investigated twelve patients-derived xenograft models from ten BRAF inhibitor 
progressed melanoma patients [12]. Proteomics analysis revealed activation of mitogen-
activated protein kinases (MAPK) and the phosphoinositide 3-kinase (PI3K) pathways, while 
genomic profiling indicated presence of several mutations that have been previously 
associated with drug resistance (e.g. NRAS, MEK1, BRAF amplification, and PTEN 
deletion). Based on these observations, agents targeting the identified resistance 
mechanisms showed anti-tumour activity, with the most efficient treatment being based on 
combination of Capmatinib, Encorafenib and Binimetinib [12]. In another study, Kim et al. 
developed a framework for the application of proteomics profiling using Reverse-Phase 
Protein Array to predict drug sensitivity [13]. As a test case, the effect of twenty four drugs 
was examined in lung cancer cell lines [13]. Based on the proteomics data and the level of 
drug tolerance, several models were developed to predict drug sensitivity by using an 
augmented naive Bayes classifier. When considering the performance of the models based 
on 20 selected proteins, the predictive accuracy was in the range between 87% and 100%. 
Last but not least, Li et al. aimed at assessment of treatment response in patients with IgA 
nephropathy [14]. Quantitative plasma proteomics profiling of samples acquired prior and 
after steroid treatment enabled calculation of “patient-to-health distance” (the level of the 
change between diseased status and health condition), which was further correlated with 
treatment response [14]. 
iii. Patient stratification 
Improvements have been made concerning the use of molecular profiling to guide the 
therapeutic intervention across a broad range of pathological conditions in the field of 
oncology [15-17], cardiology [18] and ophthalmology [19] and chronic kidney disease (CKD) 
[20-27]. Patient stratification was performed on the basis of proteome analysis alone, or in 
combination with multi-omics profiling data from tissue or body fluids. Subbiah et al. applied 
next-generation exome sequencing, immunohistochemistry (IHC) and fluorescent in situ 
hybridization to guide the treatment of two patients with osteosarcoma [15]. Molecular 
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analysis releveled aberrations in P1K3CA, c-MET, SPARC and COX2 (for the first patient) 
as well as NF2, PDGFRα and TP53 (for the second patient). Guided by the individual 
molecular profiles, therapies targeting the detected changes were administrated [15]. 
However, the therapeutic benefit of the molecular-guide treatment was not obvious [15]. 
Malara et al. targeted assessment of the risk of metastasis of patients with colon cancer 
using circulating tumour cells (CTCs), supplemented with proteomics profiling [17]. Based on 
the growth pattern in vitro, short-time expanded CTCs could be clearly categorized into two 
subsets i.e. CD45CD133+ and CXCR4+CK20+. Similarly, different biological behavior in vitro 
was noted for each subset: tumourigenic (for CD45CD133+) and disseminating (for 
CXCR4+CK20+). Importantly, patients with prevalence of CD45CD133+ CTCs showed a 
lower overall survival, while those with prevalence of CXCR4+CK20+ CTCs showed a low 
disease-free survival. In a study by Kartashova et al., treatment selection for patients with 
isolated systolic hypertension was performed on the basis of plasma proteome-based 
interactome network [18], while Velez et al. applied cytokine profiling of vitreous fluid biopsy 
to support the therapy of patients with posterior uveitis [19]. Cytokine profiling data from 20 
subjects (15 patients with different types of uveitis and 5 controls) were used to better 
characterise a new disease case initially diagnosed with idiopathic uveitis. Based on the 
clustering approach, individual cytokine expression profile classified the new patient together 
with other cases with defined autoimmune retinopathy. However, at the time of the 
diagnosis, there was no sign indicating the autoimmune retinopathy. Guided by cytokine 
profiling, presence of antibodies against S-arrestin (known cause of autoimmune uveitis) 
was assessed and confirmed the molecular-based diagnosis [19]. Hence, earlier and more 
effective therapeutic intervention could be possible. In another study, Srivastava et al. 
applied radio-proteomics strategy to identify biomarkers associated with radioprotection. As 
a test case, human hematopoietic CD34+ cells from healthy individual were treated with 
tocopherol succinate for a period of 24 h, followed by radiation [16]. Proteins significantly 
affected by the investigated compound were involved mostly in epigenetic regulation, DNA 
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repair, and inflammation [16]. Aiming at improving the management in patients with chronic 
kidney disease, a mass spectrometry (capillary electrophoresis coupled to mass 
spectrometry, CE-MS) based panel of 273 urinary proteins was developed [20], including 
among others peptide fragments of extracellular matrix proteins and proteins related to 
inflammatory processes and the disease pathophysiology. The so called CKD273 peptide 
panel was initially introduced and validated further for early stage disease detection in 
several, yet relatively small studies [25, 27, 28]. Promising results from these studies paved 
the way towards verification of the developed peptide panel in large patient cohorts, further 
expanded to include diabetic patients, but also the general population [21, 23, 24, 26]. A 
significant improvement over the currently applied standard means could be demonstrated 
for CKD273, enabling earlier and more accurate assessment of CKD, especially diabetic 
kidney disease. This led to the initiation of the first urine proteomics guided intervention trial, 
PRIORITY [22]. In this randomized controlled clinical trial more than 2000 diabetic patients 
were included. Patients positive for CKD273 (indicating early stages of CKD) are 
randomized for a low dose treatment with an aldosterone antagonist (spironolactone) with 
renoprotective properties or placebo. As a result of these studies, the U.S. Food and Drug 
Administration Organization (FDA) has recently issued a Letter of Support for CKD273 
(http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/UCM508790.pdf). 
iv. Identification of novel drugs/ drug targets 
Multidimensional –omics profiling datasets have been applied for the comprehensive 
characterization of the tumour-related changes, resulting in identification of novel targets for 
therapeutic intervention. Agren et al. utilized a genome-scale metabolic model (GEM), to 
identify anti-metabolites (i.e. drugs that are structural analogs to metabolites), which could 
serve as novel drugs for hepatocellular carcinoma (HCC) [29]. The GEM was reconstructed 
on the basis of IHC-based profiling data, task-driven Integrative Network Inference for Tissue 
algorithm and the Human Metabolic Reaction database 2 [29]. Further treatment with 
antimetabolites of L‐carnitine that have not been evaluated so far resulted in the reduction of 
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HepG2 cell viability when comparing to untreated cells. Ding et al. proposed the identification 
of drug targets through the assessment of protein and mRNA expression of mutated tumour 
alleles (independently on the mutation frequency) using –omics profiling [30]. Assuming that 
the altered proteins derived from the mutated alleles can be targeted for therapeutic 
intervention, proteome profiling, whole-exome sequencing and RNA-sequencing was carried 
out in a hyper-mutated patient suffering from HCC. Combination of –omics data with 
functional analysis using Ingenuity software allowed for prioritization of the candidate 
mutated driver genes (HNF1A, IDH1, FAH, GNMT, and SPTBN1). Three of them were 
selected and successfully validated using SRM (HNF1A, FAH, SPTBN1) [30]. Along these 
lines, Brown et al. applied a combination of morphoproteomics, genomics and personalized 
tumour graft testing in the context of one of the subtypes of Alveolar rhabdomyosarcoma 
involving a fusion transcript of PAX3-FKHR (FOXO1 gene) [31]. Combination of these data 
sets unravelled mechanisms associated with the disease, and allowed for the identification 
of possible therapeutic targets [31]. 
C. New methodological concepts 
The analytical workflows behind personalized medicine are complex and frequently require 
integration of multi-omics data sets through advanced computational tools. Several groups 
have targeted the improvement of proteomics techniques and related workflows to advance 
personalized medicine. Syafrizayanti et al. established a methodology to produce protein 
tissue microarrays representing full length proteins of individual samples [32]. Longuespée et 
al. developed a protocol for the identification of proteins detected by matrix assisted laser 
desorption/ ionization (MALDI) imaging/ profiling [33]. Novel approaches for personalized 
cancer research involve the investigation of organoids derived from patients’ excised tissue 
samples. Along these lines, proteomics characterization of organoids derived from colorectal 
tumour and matched healthy-derived tissue revealed multiple features that have been 
previously linked to colorectal cancer e.g. unconventional myosin-Ic, Desmocollin-2, 
Paralemmin-3, Adhesion G-protein coupled receptor G1 and others [34]. Moreover, efforts 
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have been undertaken to improve data sharing in scientific community and computational 
approaches have been developed to support the –omics data cross-correlation. It has to be 
underscored that, although several public repositories for storage of the –omics data are 
available, such as PRIDE PRoteomics IDEntifications [35], PeptideAtlas [36] (for proteomics 
data), ArrayExpress [37], Gene Expression Omnibus [38] (for microarray data), 
MetaboLights [39] (for metabolomics data), they are mostly dedicated to the storage and 
handling of individual –omics traits. Recently, Bauer et al. developed a web-based tool called 
“BioMiner”, which provides access to high-throughput cancer-related -omics datasets as well 
as to an analytical toolbox designed for multi-omics data analysis [40]. Furthermore, 
algorithms supporting the analysis and visualization of treatment response data have been 
presented. Bouwman et al. described a statistics-based visualization method (called “health 
space”) on the basis of the pre-selected biological processes defined through the analysis of 
–omics data sets (i.e. proteomics, transcriptomics, metabolomics) [41]. This methodology 
was applied to describe an effect of the nutritional intervention in a group of 36 subjects, 
allowing for the discrimination of treated and untreated individuals as well as assessment of 
the biological processes modulated in these groups [41]. 
D. Personalized medicine in Bladder Cancer 
The need for developing precision medicine is rising given that patient response rates to the 
drugs reach only 25% efficiency in cancer [42]. There appears to be no study yet demonstrating 
the successful application of either proteomics or other –omics technology in personalized 
medicine. However, as outlined in the course of recently published review articles [43-45], 
substantial progress has been made towards the identification of proteomics-derived 
biomarkers as well as putative targets for therapeutic intervention to support patient 
management (diagnosis, monitoring, stratification and treatment) in bladder cancer. Urothelial 
carcinoma or bladder cancer is a disease, where personalized medicine seems ideally suited to 
improve on its management, given: a) the epidemiological and clinical facts, b) the intrinsic 
heterogeneity of the disease and thus, c) the lack of effective treatment. Therefore, in the 
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subsequent part of this manuscript, a critical assessment of the current status of proteomics 
developments in the field of bladder cancer personalized medicine is presented. 
i. Epidemiological/ clinical facts 
Bladder Cancer is the second most common cancer of the genitourinary tract, the 4th most 
common cancer in men and the 11th most common in women [46]. Based on 
histopathological examination, when considering the extent of the spread of tumour cells into 
the bladder wall, bladder cancer is classified as non-muscle invasive (cancer cells are 
confined to urothelium, NMIBC), muscle-invasive disease (when cancer cells have spread 
into muscle layer of the bladder, MIBC) and metastatic disease (when cancer cells have 
spread outside the bladder). So far, the recommended treatment for NMIBC is transurethral 
resection and Bacillus Calmette-Guérin (BCG) intravesical immunotherapy [47]; whereas for 
MIBC is radical cystectomy, (neo)adjuvant chemotherapy or (chemo)radiotherapy [48-50] 
and the recently approved immunotherapy targeting the Programmed death-ligand 1 
molecule. Even though, the majority of patients (~70%) are initially diagnosed with the non-
muscle invasive disease [51] with favourable clinical outcome (5-years survival rate is in the 
range of 98-88%), the probability of disease recurrence (31-78%) and progression (0.8-45%) 
within 5 years’ time is very high, with approximately 40% of the NMIBC patients not 
responding to BCG treatment. Consequently, BC patients need to be continuously monitored 
using invasive cystoscopy, dependent on the patients’ degree of risk (as assessed though 
the European Organisation for Research and Treatment of Cancer scoring system and risk 
table [47]). So far, no alternative non-invasive tool to replace cystoscopy is accepted in the 
guidelines [47]. Considering this fact, development of non-invasive tools to guide cystoscopy 
and reduce its frequency during the follow-up monitoring of BC is expected to improve BC 
patient management. Implementation of such biomarkers would have a significant impact on 
the patient management, e.g. through guidance of cystoscopy (Figure 2). Negative results of 
the test would allow avoiding unnecessary cystoscopy, while positive result could increase 
urologist alertness to perform more thorough examination. For patients that are at risk for 
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disease recurrence and undergo frequent monitoring, application of the non-invasive test 
would decrease the number of invasive cystoscopies. Considering that biomarker tests 
cannot reach ultimate sensitivity levels (100%), misclassification of some patients will occur, 
but this is also observed in cystoscopy. Further, due to the frequent follow-up, particularly 
during surveillance (which for high risk cases, examination every three months is 
suggested), it is expected that misdiagnosed tumours will be correctly detected later during 
the follow-up. 
ii. Addressing disease heterogeneity 
Molecular profiling data revealed that bladder cancer is a highly heterogeneous disease. The 
classical classification is based on two pathologically distinct progression forms, called 
papillary and non-papillary [52, 53]. The currently available data suggest that papillary BC 
(stratified as NMIBCs) evolves from hyperplasia of the urothelium through disruption on the 
phosphatidylinositol-3-kinase/ Akt and the mammalian target of rapamycin (PI3K-AKT-
mTOR), Fibroblast growth factor receptor 3 and GTPase HRas [54] pathways, while non-
papillary expansion (clinically stratified as MIBC) evolves through urothelial dysplasia and 
carcinoma in situ caused by alterations in TP53, CDKN2A, CCND1, CDKN1B and RB1 [54]. 
Molecular characterization at the genetic level based on next generation sequencing data 
[55-59], suggested a new sub-classification involving of NMIBC and MIBC, based on 
mutation status of epithelial cytokeratins HIF-1, EGFR, FGFR, ERB as well as PI-3 
kinase/AKT pathway [60]. The presence of additional molecular disease subtypes has been 
suggested by various groups (as summarized in [61, 62]) nevertheless, with a consensus on 
clinical decision making not having been reached yet. Due to the increased BC 
heterogeneity and as the individual molecular profile has a significant impact on disease 
aggressiveness and drug response, therapeutic decision making based on the classical 
histopathological assessment of the tumour tissue is not always successful. A detailed 
investigation of the molecular alterations underlying BC appears to present an ideal basis for 
the establishment of personalized therapeutic interventions [56, 63]. This could possibly also 
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decrease the economic burden of bladder cancer: lifetime treatment costs per patients are 
the highest among all cancer types [64]. This is also evident based on the estimates for the 
BC related health care costs for year 2012, reaching up to €2.87 billion in 2012, which 
accounts for 5% of the total cancer health expenditure) [65]. While reliable biomarkers for 
patient stratification are currently not available for clinical use, the newly designed clinical 
trials highlight the value of companion tests, like prognostic and predictive biomarkers and 
stratification tools to guide intervention [56, 66, 67]. 
iii. Proteomics to support personalized medicine in BC 
As shown above, the application of clinical proteomics represents a promising strategy to 
address the challenges related to BC patients’ management. For that purpose, a broad 
range of biological specimens, that best reflect molecular changes associated with the 
pathological condition, was investigated using different proteomics platforms. In the context 
of BC, the main research focus has been placed on the assessment of urine and tissue 
proteome (Figure 2). Through the direct contact with the bladder tumour, the urinary 
proteome is expected to be enriched in proteins reflecting the tumour development and 
invasion. Moreover, urine can be obtained non-invasively, shows increased stability over 
serum/ blood and it allows for easy multiple sampling. Investigation of the urinary proteome 
has been mostly applied for identifying non-invasive biomarkers for diagnosis of primary and 
recurrent BC as well as assessment of disease-aggressiveness. 
Although urine proteome analysis enables the identification of biomarkers, it generally does 
not provide a direct link to the disease pathophysiology. This can be achieved, though, by 
tissue proteomics, since tissue represents a direct site of disease initiation and progression. 
Tissue proteomics can provide insights into disease-associated mechanisms, thus identify 
best suited biology-driven therapeutic targets. Collectively, urinary proteome profiling can be 
used to support personalized disease diagnosis/ monitoring and stratification; while tissue 
proteomics can address the concept of personalised therapeutic intervention, through 
identification of novel therapeutic targets (Figure 3). In the following sub-sections, an 
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overview on the proteomics studies addressing the above mentioned clinical applications 
using the state-of-the-art MS-based platforms is given. 
- Diagnosis and monitoring of bladder cancer 
Up to now, several urinary biomarkers have been described, among others the FDA 
approved immunoassays, which measure the urinary levels of Bladder cancer associated 
antigen (BTA stat) and Nuclear matrix protein 22 (NMP22), presenting however, with 
moderate performance (NMP22: 68% sensitivity, 79% specificity [68]; BTA Stat: 61% 
sensitivity, 78% specificity [69]). Additionally, several single protein biomarkers have been 
thoroughly investigated, including Matrix metalloproteinases (Matrix metalloproteinase-9, 
Matrix metalloproteinase-10), angiogenic factors (Plasminogen activator inhibitor 1, Vascular 
endothelial growth factor, Angiogenin, Apolipoproteins (Apolipoprotein A-I, Apolipoprotein A-
II, Apolipoprotein E), Interleukin-8 and Carbonic anhydrase 9, as recently reviewed [44], 
mainly assessed by immunoassays (ELISA). However, several limitations, involving lack of 
appropriate diseased matched controls in the studies, as well as difficulties related to the 
analytical validation of ELISA urine based assays [70], shifts the research focus towards the 
application of mass spectrometry based platforms for the development of clinically useful 
biomarkers. Particularly Multiple reaction monitoring (MRM) [71] and CE-MS [24, 26, 72-74] 
are two mass spectrometry based platforms that can support well powered validation studies 
and are proven to be applicable in clinical practice. 
In bladder cancer, MRM has been applied to validate previously reported biomarkers, among 
others Complement C4 gamma chain, Apolipoprotein A-II precursor, Ceruloplasmin and 
Prothrombin in a small set of 76 BC patients and 23 disease relevant controls (including 
urinary tract infections and patients presenting with hematuria) [75]. Although promising, the 
performance of the MRM-based peptide panel showed a value for area under the curve 
(AUC) of 0.81, this approach must be further validated in a larger prospective study. In a 
recent study by Guo et al. [76], ten proteins (including Cytochrome c oxidase subunit 3, L-
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lactate dehydrogenase B chain, Basement membrane-specific heparan sulfate proteoglycan 
core protein, Fibronectin, Cadherin 1 and CD44 antigen) initially investigated in secretome 
analysis of BC cell lines by isobaric tags for relative and absolute quantitation (iTRAQ) and 
two-dimensional electrophoresis (2DE), were validated in 23 urine samples from BC patients 
and 24 urine samples from healthy individuals [76]. The MRM verification resulted in AUC 
values ranged between 0.66 and 0.84. However, the use of healthy individuals as controls 
and the low number of the recruited patients underscores the need for further investigations 
in appropriate design settings. 
In parallel, CE-MS based urinary proteome analysis has been applied in the context of BC, 
as reported [73, 77, 78], aiming at: 1) discovering diagnostic biomarkers that enable 
detection of BC [78], 2) validating discriminatory biomarkers to sub-classify between non-
muscle and muscle invasive disease [77] and 3) detecting primary and recurrent BC in 
clinical settings [73]. The above studies are summarised in Table 1. The first study was 
performed by Theodorescu et al. in 2006 [78], where a panel of 22 urinary biomarkers was 
established in a small cohort of BC patients and healthy individuals (N = 121) [78]. Validation 
in independent samples (31 patients with BC and 366 controls) resulted in 100% sensitivity 
and 73% specificity [78]. Even though the performance of this biomarker panel provides a 
good discriminatory accuracy for detection of advanced BC in the general population, the 
performance was limited when the classification of less advanced cases was attempted. To 
address this issue, in a study by Schiffer et al. [77], a biomarker panel comprised of 4 urinary 
peptides was established to differentiate between patients with NMIBC and MIBC. Further 
inclusion of the tumour grade increased the discriminatory capability and resulted in the 
sensitivity of 92% and specificity of 68% [77]. As a follow-up of these studies, a large multi-
centric study (including 5 clinical centres from Europe and USA, n = 1357) was designed, 
with the experimental set-up reflecting well the clinical situation [73]. In this study, two multi-
marker panels comprised of 116 and 106 urinary peptides were established for the purpose 
of detecting primary (n = 721) and recurrent bladder cancer (n = 636), respectively, resulting 
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in AUCs of 0.87 and 0.75, respectively [73]. Among the peptide biomarkers that are included 
in the CE-MS panel are several Fibrinogen chains, Apolipoprotein A1, Beta-2-macroglobulin 
and Basement membrane-specific heparan sulfate proteoglycan, that have also been 
described as single protein biomarkers in BC proteomics studies [44]. In the above 
investigation the urinary profiling data also reflected disease progression, as displayed in 
Figure 4. Further, a significant correlation of peptide abundance with disease stage and 
grade was reported [73]. 
- Patient stratification 
Although a study demonstrating a clear value of proteomics biomarkers as stratification tools 
has not been published yet, initial data indicate substantial value and support the idea of 
using proteomics for patient stratification. So far, the main aim in the investigation of proteins 
in the context of BC progression involved the correlation of tissue expressed protein 
biomarkers with the disease outcome. As such, the vast majority of the tissue proteomics 
studies involved single biomarkers investigated by immunohistochemistry (IHC) and tissue 
microarrays. An overview of such tissue biomarker studies in BC was recently published 
[44]. In brief, proteins like Cystatin B, extracellular matrix and cytoskeletal related proteins 
(Actin, Desmin, Vimentin, Annexin, Profilin-1) and others like Histone 2B, bladder cancer-
associated protein (BLCAP) and p54 were reported to be significantly associated with BC. 
Although promising, these biomarkers cannot serve as non-invasive prognostic/ stratification 
tool and provide limited information on the affected molecular pathways. Urinary biomarker 
panels seem to be better suited in guiding personalized intervention. As described in the 
study by Frantzi et al. [73], CE-MS urinary profiling data can reflect disease progression to 
MIBC, indicated by the gradual change in the abundance of the urinary peptides along with 
cancer progression [73]. Preliminary results support the use of urinary peptide profiling as a 
tool for non-invasive patient stratification, as patients with a positive scoring for urinary 
based-test have significantly lower survival probability than patients with negative scores, at 
the defined endpoint which was the time to disease relapse (Belczacka, Frantzi et al., 
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unpublished data). Therefore, a study investigating the benefits of urinary proteome-guided 
personalized intervention seems warranted, to investigate the potential value of urinary 
profiling for patient stratification by enabling earlier intervention and consequently improved 
survival and quality of life. 
- Identification of novel drugs/ drug targets 
Mass spectrometry based tissue proteomics was applied initially aiming towards a better 
understanding of disease-associated molecular pathophysiology. First studies have been 
published aiming at increasing our knowledge for the disease related proteins and 
associated pathways and have been recently reviewed in [43, 44]. Initially, no clear 
indication for potential drug targets was reported. This concept, however, was recently 
addressed in a study by Peng et al. where Phosphoglycerate mutase 1 (PGAM1) was initially 
identified as significantly up-regulated in BC compared to adjacent normal tissue by 2DE 
[79]. Moreover, the protein level of PGAM1 has been found to be significantly correlated with 
the disease grade using IHC on a total of 90 tissue samples (i.e. 60 BC tissue and 30 
adjacent normal tissue samples). The functional relevance and anti- tumour potential upon 
inhibition was further investigated [79]. Silencing of PGAM1 using shRNA decreased tumour 
growth and cell proliferation and increased apoptosis in vivo. While the comparison between 
normal urothelium and cancer tissue does not ideally reflect disease progression from 
NMIBC to MIBC, this study serves well as a proof-of-principle. 
In a further advancement, a study investigating a total of 11 tissue samples was published, 
aiming at detecting differences in the proteome profile between NMIBC (n = 5, stage pTa) 
and MIBC (n = 6, stages pT2+). Using high-resolution LC-MS/MS [80], 144 proteins 
associated with cancer invasion were identified, including multiple proteins previously linked 
to BC including but not limited to some Annexins, Alpha actinins, Cathepsin E, 
Hydroxyprostaglandin dehydrogenase 15-(NAD), Thymidine phosphorylase and others. 
Importantly, through the in silico analysis, Eukaryotic translation initiation factor 3 subunit D 
was identified as a promising target for intervention (up-regulated in MIBC vs NMIBC), and 
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its functional relevance was investigated using in vitro and in vivo disease models [80]. 
Specifically, it has been demonstrated that stable knockdown of EIF3D using lentivirus-
mediated RNA interference in a metastatic BC cell line (T24M) resulted in decreased cell 
proliferation, migration capacity and colony formation. Subsequent investigation in xenograft 
models showed a decrease in the tumour growth. These recent studies highlight the 
potential of the use of tissue proteomics based approach to identify new drug targets for 
bladder cancer. 
Proteome analysis has been applied to investigate effect and molecular mechanisms of novel 
potential drugs for BC. Li et al. [81] assessed the effect of five HSP90 inhibitors (AUY922, 
ganetespib, SNX2112, AT13387, and CUDC305) in vitro using the 5637 urinary bladder cancer 
cell line, followed by quantitative proteome analysis at the global and histones post-translational 
modifications levels. HSP90 inhibitors suppress cell proliferation and growth in a dose and time 
dependent manner. LC-MS/MS analysis resulted in the identification of 518 over twofold up- 
and 811 more than twofold down-regulated proteins that were commonly de-regulated upon 
treatment with AUY922 and ganetespib. This includes among the others, proteins involved in 
the regulation of cell cycle (several Cyclins, Cyclin-dependent kinases, Cullin-1, DNA replication 
licensing factor MCM 5 and others), apoptosis (Apoptosis regulator BAX, Caspase-14, Calpalin-
7, Apoptosis inducing factor 1 and others), DNA damage repair (DNA ligase 3, DNA repair 
protein XRCC1 and others) as well as generation of reactive oxygen species (Gluthation 
peroxydases, Gluthathione S-transferases, Superoxide dismutase [Mn] etc). 
iv. Health economic aspects 
Considering the emerging need on improving the BC patient management, studies assessing 
the cost- effectiveness of bladder cancer biomarkers have been published, mainly including the 
comparative investigations of the FDA approved urinary biomarkers [fluorescence in situ 
hybridisation (FISH), ImmunoCyt, NMP22] and cytology with the current diagnostic standard, 
which is cystoscopy [68, 82]. For the above economic evaluations, the decision model included 
the biomarker tests and cytology, as means to guide cystoscopy. As such, the positive result of 
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the biomarker/cytology test should be further confirmed with cystoscopy, while true negative 
results will not warrant further investigation. According to the results the application of 
Immmunocyt (with estimated pooled sensitivity of 84% and specificity of 75%), followed by 
cystoscopy, was the most cost-effective strategy [68]. Regarding the proteomic derived 
biomarkers, a health economic evaluation was performed based on the results of the CE-MS 
based biomarker panels [43], in the context of TransBioBC European project (Project ID: 
601933). The results indicated that a test at cost <600€, which is not higher than the costs 
associated with white light cystoscopy would be cost effective, in guiding the cystoscopic 
procedures. In particular, the decrease in the number of unnecessary cystoscopies (resulting 
from the use of the urinary based CE-MS biomarkers) is expected to decrease the disease 
associated costs. 
E. Outlook 
Based on the evidence accumulated over the last five years and driven by advancements in the 
proteomics workflows, computational tools and applicability of -omics data cross-correlation, 
employing proteome analysis to support personalized medicine now becomes feasible. The 
approach is expected to improve personalized healthcare through the better assessment of the 
disease risk, more accurate diagnosis and disease monitoring and also targeted treatment. 
However, the level of evidence supporting the feasibility of the translation of individualized 
molecular profiles into routine application is still quite moderate. Specifically, limited statistical 
power and lack of proper validation conducted in large independent sets of samples are main 
points that still remain to be addressed. The most effective approach in this respect appears to 
be the investigation of multiple approaches in parallel in the same population, as suggested 
recently [83]. Moreover, better computational approaches are required to further support the 
transfer of the personalized medicine into clinical routine. 
Regarding BC and the need for biology-driven drug targets, several studies demonstrate the 
value of tissue proteomics profiling. Moreover, extensive research conducted has enabled 
discovery and validation of diagnostic and prognostic proteomic biomarkers for bladder cancer. 
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However, the use of state-of-the-art proteomics approaches for assessment of treatment 
response or patients’ stratification remains to be addressed. Given the complexity of action of 
the drugs, a rational prediction of proteins related to drug response does not appear suitable 
using a single marker test. Therefore, the most credible approach appears to be the 
investigation of the entire proteome, aiming to better understand the mechanisms associated 
with drug response, and development of high-dimensional multi-marker classifiers. Similarly, 
implementation of single biomarkers for disease diagnosis/ monitoring may not be successful 
due to the high heterogeneity of BC. Thus, the focus has shifted to the evaluation and 
establishment of biomarkers panels, consisting of multiple biomarkers that reflect more 
accurately the disease associated changes and heterogeneity, in comparison to the single 
biomarkers. In combination with the data from tissue proteome analysis and the anticipated 
outcome, additional specific drugs, it is foreseeable that bladder cancer may be one of the first 
examples for the application of proteomics-driven personalized medicine. 
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Figure Legends 
Figure 1. High-resolution proteomics data from tissue and urine enable the identification of 
protein changes in pathological conditions. Combined with extensive literature data, 
modeling of the disease can be achieved and target the disease associated molecular 
pathways. Key components of these pathways can be then verified in human tissue. This 
builds a foundation for the identification of biology-driven therapeutic targets. In parallel, 
animal models can be investigated for molecular homology, enabling to choose the model 
system best reflecting the human disease. Interference studies in this model enable 
assessing its relevance in disease, guiding the development of drugs truly addressing 
molecular cause of disease. Therefore, together with the assessment of the individual urine 
proteome, this will support personalized medicine. 
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Figure 2. Overview on the applicability of urinary (A) and tissue proteomics (B) to improve 
Bladder Cancer patients’ management. Schematic representation of the proposed context of 
use of proteomics profiling is given, considering: a) patients’ diagnosis and monitoring (for 
urinary biomarkers) and b) the identification of novel therapeutic targets and prediction of 
treatment response (tissue profiling/ urine biomarkers). Abbreviations: BMs – biomarkers; 
NMIBC – Non-muscle invasive bladder cancer; MIBC – muscle invasive bladder cancer. 
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Figure 3. Proteomics in the quest of bladder cancer personalized therapy. A schematic 
representation of the potential use of proteomics-based molecular profiles of urine and tissue 
is provided. In actual application, classifiers to predict the response to the known drugs are 
expected to be applied, in order to provide a score depicting the likelihood of response to the 
respective drug. Consequently, the drug with highest scoring will be chosen for therapy, to 
increase the success rate of the therapy. In the next step, classifiers to predict the disease 
progression and also monitor the treatment effect in a non-invasive way are applied. In case 
of a positive result for disease progression, alternative/ more efficient treatment will be then 
selected. Abbreviations: BC – Bladder Cancer. 
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Figure 4. Urinary proteomics profiling data reflect tumour stage. Three-dimensional urinary 
profiles were generated by plotting the CE-retention time (x-axis), mass (y-axis) and intensity 
(z-axis) of identified peptides. Abbreviations: CIS – carcinoma in situ. 
 
Supplementary Table 1. List of the 20 relevant manuscripts in the context of proteomics and 
personalized medicine retrieved from the literature mining.
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Table 1. CE-MS urinary proteomics-based investigations in Bladder Cancer. 
 
 
 
www.clinical.proteomics-journal.com Page 40 Proteomics - Clinical Applications 
 
This article is protected by copyright. All rights reserved. 
40 
 
 
 
 
www.clinical.proteomics-journal.com Page 41 Proteomics - Clinical Applications 
 
This article is protected by copyright. All rights reserved. 
41 
 
 
 
Abbreviations: APOA1 – Apolipoprotein A-I, ADAMTS1 – Disintegrin and metalloproteinase with thrombospondin motifs 1, ADAM22 – Disintegrin and metalloproteinase domain-containing 
protein 22, B2M – B2-microglobulin, BC – Bladder Cancer, COL1A1 – Collagen α-1 (I) chain, COL3A1 – Collagen α-1 (III) chain, FIBA – Fibrinogen alpha chain, HBA – Hemoglobin A, HRG – 
Histidine-rich glycoprotein, HSPG2 – Basement membrane-specific heparan sulfate proteoglycan core protein, INS – insulin, MIBC – Muscle invasive Bladder Cancer, NMIBC – Non-muscle 
invasive Bladder Cancer, PGRMC1- Membrane associated progesterone receptor component 1, SPRR3 – small proline-rich protein 3, UMOD – Uromodulin 
 
